Trials / Completed
CompletedNCT05599828
A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
An Open-label Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics of AMG 510 in Healthy Subjects Under Fed Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this study is to evaluate the PK of AMG 510 alone and in combination with either famotidine or omeprazole in healthy participants under fed conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 510 | Oral Tablet |
| DRUG | Omeprazole | Capsule |
| DRUG | Famotidine | Tablet |
Timeline
- Start date
- 2020-07-17
- Primary completion
- 2020-09-13
- Completion
- 2020-09-13
- First posted
- 2022-10-31
- Last updated
- 2024-12-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05599828. Inclusion in this directory is not an endorsement.